Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Ann N Y Acad Sci. 2020 Feb 6;1479(1):94–107. doi: 10.1111/nyas.14311

Figure 2.

Figure 2.

Dose-dependent effect of midazolam (MDZ) on survival following GD-induced status epilepticus in ES1−/− mice. Mice exposed SC to 82 μg/kg of GD and treated with 1 mg/kg MDZ (GD/MDZ1; P < 0.001; n = 11) or 3 mg/kg MDZ (GD/MDZ3; P = 0.001; n = 26) had a significantly lower mean survival time compared with control (No GD; n = 14), while those treated with 9 mg/kg (GD/MDZ9; n = 14) were not significantly different from No GD control. The GD/MDZ1 and GD/MDZ3 groups also had a significantly lower mean survival time compared with the GD/MDZ9 group of mice. The percent of survival at study endpoint is also shown in graph. GD/MDZ1 (***P < 0.001) and GD/MDZ3 (**P < 0.01) had significantly lower survival compared with No GD, while the GD/MDZ9 group was not significantly different from No GD control. The dose-dependent effects of midazolam were independent of sex.